John has been covering financial markets since before the FTSE 100 existed, starting out on the Industries and Commodities team at Dun & Bradstreet, before moving on to Datastream, where he was head of the news team for several years. After a succession of management roles at Thomson Reuters he returned to front-line journalism in 2006. Prior to joining Proactive Investors he was managing editor at Sharecast.
Faron expects to receive the interim results from the INFORAAA study of Traumakine in the near future, allowing a full review of all the Traumakine data with key opinion leaders, after which Faron will make the final decisions on Traumakine's development.
"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas," said Dr Tim Mitchell, the Sareum CEO.
"We have important milestones ahead of us, including our first site in Harley Street which we expect to be soon ready for fit-out, and we reiterate our commitment to treat our first patients towards the end of 2020," said chief executive officer, Nicolas Serandour
Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
"We are delighted that Stephen has joined ProBiotix Health at such an exciting stage of its development and hope that under his leadership it can grow to become a substantive and valuable business in the years ahead," said Stephen O'Hara, the CEO of OptiBiotix
The Stoer For Men skin care range was at monthly break-even by year-end 2018.
"I'm very pleased that Rob will serve as full-time chief financial officer and on behalf of the board I would like to formally welcome him to this role," said David Horn Solomon, Silence's CEO
Securing approval in the US for iclaprim remains the top priority for Motif Bio, the company said as it posted full-year 2018 results which saw losses narrow sharply
Our tweaked UK take on the famous "Dogs of the Dow" strategy performed very well in its first year (to end January 2018) but pooped on the pavement in the second year
Stockpot's "AIM sustainable dividends" virtual portfolio was conceived as a way of screening out the "jam tomorrow" companies on AIM to focus on those companies capable of paying rising dividends. The last couple of months have seen almost 18 months of gains wiped out.
In another update on the "mindless momentum" mechanical investment strategy - this time on small caps worth less than £100mln - nine of the 10 stocks head for the door having failed to sustain their momentum.
After setting the IPO price at the bottom of the range failed to prevent a disastrous stock market debut for Funding Circle, the stock is beginning to recover. It's a tricky stock to value because of the alleged disruptive nature of the peer-to-peer (P2P) lending model but in the US, investors seem a lot more sceptical about...